European regulators expand Pfizer vaccine approval

European regulators have become the first to approve Pfizer Inc.'s Prevenar 13 vaccine for patients at all stages of life by including adults between the ages of 18 and 49.

The New York drugmaker said Wednesday that the vaccine, known as Prevnar 13 in the United States, had already been approved in the Europe Union for infants and children up to age 17 as well as adults ages 50 years old and older.

The vaccine protects against 13 strains of , which can cause meningitis, pneumonia and . It is the biggest-selling vaccine in history and brings in nearly $4 billion in annual revenue.

In the United States, Prevnar 13 is approved for use in infants and children up to age 17 and adults 50 and older.

Pfizer shares rose 8 cents to $28.43 in premarket trading about an hour before the market opens.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA reviews update to Pfizer vaccine for kids

Nov 16, 2009

(AP) -- Federal health officials on Monday questioned whether to approve an updated version of Pfizer's best-selling anti-infection vaccine for children, despite company studies that failed to meet certain goals.

Study to test pneumococcal vaccine in older adults

Oct 15, 2012

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

Wyeth seeking approval for advanced infant vaccine

Mar 31, 2009

(AP) -- Drugmaker Wyeth on Tuesday sought U.S. approval to sell a new version of its blockbuster infant vaccine Prevnar that protects against more strains of a bacteria that causes pneumonia and other diseases.

Pfizer Q1 profit up, but drugmaker cuts outlook

Apr 30, 2013

Pfizer Inc.'s first-quarter net income rose 53 percent despite falling sales, mainly because the world's second-largest drugmaker took big charges a year ago. Pfizer's results fell short of Wall Street's ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

4 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments